<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536625</url>
  </required_header>
  <id_info>
    <org_study_id>RAPANK</org_study_id>
    <nct_id>NCT02536625</nct_id>
  </id_info>
  <brief_title>Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)</brief_title>
  <acronym>RAPANK</acronym>
  <official_title>RAPANK: Study of the Impact of Everolimus Treatment on the Development and Functions of Lymphocytes NK (Natural Killer), for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Biostatistics and Therapy Evaluation Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NK (Natural Killer) cells are important in the fight against tumor, especially for the
      control of cancer metastasis. The purpose of this prospective study is to evaluate the impact
      on lymphocytes NK functions and development of an everolimus treatment in women treated for a
      metastatic breast cancer. In particular, the study of lymphocytes NK functions and
      development under everolimus treatment could permit to validate an early biomarker of the
      impact of everolimus on these NK cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of the level of Granzyme B (GzmB)</measure>
    <time_frame>Timepoint at 3 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <description>Immunomonitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>prospective study</intervention_name>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative) eligible for a treatment
        with everolimus in this application
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women &gt; 18 years old

          -  Metastatic breast cancer HR+ (Hormone Receptor positive), HER2/neu negative (Human
             Epidermal Growth Factor Receptor-2)

          -  ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤2

          -  Eligible to an hormonotherapy treatment combined to an mTOR (mammalian Target Of
             Rapamycin) inhibitor (i.e. SPC (Summary of Product Characteristics) modalities)

          -  Measurable disease according to RECIST 1.1 (Response Evaluation Criteria In Solid
             Tumors)

          -  Not receiving the non-authorized concomitant treatments

          -  Patient should understand, sign, and date the written voluntary informed consent form
             at the screening visit prior to any protocol-specific procedures performed.

          -  Patients must be covered by a medical insurance

        Exclusion Criteria:

          -  BMI&gt;30

          -  All dysimmune disease, history of transplantation or immunosuppressive therapy or
             corticotherapy

          -  All chronic inflammatory diseases

          -  Last chemotherapy &lt; 6 months

          -  Corticotherapy &lt;1 year and more than 1 month

          -  Restrictive diet ≤3 months before inclusion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TREDAN Olivier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PEROL David, MD</last_name>
    <phone>+33(0) 4 78 78 28 28</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Leon berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>everolimus</keyword>
  <keyword>NK</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

